Sign in Subscribe
Class action lawsuits

Cytokinetics Shareholders Encouraged to Contact Firm Regarding Possible Lead Plaintiff Appointment

Strategic Insights

— 1 min read

Investors who purchased shares of Cytokinetics, Incorporated (NASDAQ: CYTK) during the class period from December 27, 2023, to May 6, 2025, are encouraged to contact the Gross Law Firm regarding possible lead plaintiff appointment. The firm is investigating claims that defendants made false and misleading statements regarding the timeline for the New Drug Application submission and approval process for aficamten. Specifically, defendants represented that approval from the U.S. Food and Drug Administration (FDA) was expected in the second half of 2025, but failed to disclose material risks related to the Company's failure to submit a Risk Evaluation and Mitigation Strategy (REMS) that could delay the regulatory process. On May 6, 2025, it was revealed that the Company had multiple pre-NDA meetings with the FDA discussing safety monitoring and risk mitigation but chose to submit the NDA without a REMS, relying on labeling and voluntary education materials.

Key Takeaways:

  • The class period for Cytokinetics, Incorporated (NASDAQ: CYTK) is December 27, 2023, to May 6, 2025.
  • Defendants made allegedly false and misleading statements regarding the timeline for the New Drug Application (NDA) submission and approval process for aficamten.
  • The alleged misstatements occurred despite the Company's failure to submit a Risk Evaluation and Mitigation Strategy (REMS) that could delay the regulatory process.
  • The Gross Law Firm is investigating claims that Cytokinetics, Incorporated made false and misleading statements to investors.
  • Shareholders should not delay in registering for this class action.
  • The deadline to seek to be a lead plaintiff is November 17, 2025.

Statistics:

  • Class period: December 27, 2023, to May 6, 2025.
  • Alleged misstatement period: September 26, 2025.
  • PDUFA date: September 26, 2025.
  • Deadline to seek to be a lead plaintiff: November 17, 2025.

Sources:

  • The Gross Law Firm
  • Source: The Gross Law Firm
  • 15 West 38th Street, 12th floor
  • New York, NY, 10018
  • Email: dg@securitiesclasslaw.com
  • Phone: (646) 453-8903

Read more